Top

Published in:

01-01-2017 | Original Paper

Treatment of lung tumours with high-energy microwave ablation: a single-centre experience

Authors: Anna Maria Ierardi, Andrea Coppola, Natalie Lucchina, Gianpaolo Carrafiello

Published in: Medical Oncology | Issue 1/2017

Abstract

The purpose of our study is to report safety, technical success, effectiveness, local progression-free survival (LPFS) and overall survival of percutaneous microwave ablation (MWA) to treat lung tumours unsuitable for surgery. Nineteen patients with thirty-one tumours (mean diameter 2.4 cm) underwent percutaneous MWA in 28 sessions. Microwave ablation was carried out using a 2450-MHz generator (Emprint/Covidien, Boulder, CO, USA). Procedures were performed under cone-beam CT (CBCT) and under fluoro-CT (one session) guidance. Safety, technical success, effectiveness, LPFS and overall survival (OS) were evaluated. Safety was defined as the frequency of major and minor complications. The efficacy was evaluated on the basis of imaging characteristics, using RECIST criteria. CT follow-up was performed at 1, 3 and 6 months and yearly. LPFS was defined as the interval between MWA treatment and evidence of local recurrence, if there was any. OS was defined as the percentage of patients who were still alive. We registered one major complication (purulent hydro-pneumothorax). Minor complications were spontaneously resolved (pneumothorax and perilesional haemorrhagic effusion). Technical success was 100%. Residual disease was registered in two cases, one of whom was retreated. Complete ablation was obtained in the remaining cases (90.3%). During available follow-up (mean 9.6 months), 9/31 tumours demonstrated local recurrence. Five tumours were retreated, and none of them presented residual disease during follow-up (LPFS 22.6%). Overall survival was 93.8%. Percutaneous high-energy MWA is a safe, effective and confident technique to treat lung tumours not suitable for surgery.

Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thoracic Cardiovasc Surg. 1997;113(1):37–49.CrossRef

Gaudet MA, D’Amico TA. Thoracoscopic lobectomy for non-small cell lung cancer. Surg Oncol Clin N Am. 2016;25(3):503–13. doi:10.1016/j.soc.2016.02.005.CrossRefPubMed

Wei Z, Ye X, Yang X, Huang G, Li W, Wang J, et al. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. Med Oncol. 2015;32(2):464. doi:10.1007/s12032-014-0464-z.CrossRefPubMed

Ridge CA, Solomon SB. Percutaneous ablation of colorectal lung metastases. J Gastrointest Oncol. 2015;6(6):685–92. doi:10.3978/j.issn.2078-6891.2015.095.PubMedPubMedCentral

Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics: a review publication of the Radiological Society of North America, Inc. 2005; 25 Suppl 1:S69–83. doi:10.1148/rg.25si055501.

Carrafiello G, Lagana D, Mangini M, Fontana F, Dionigi G, Boni L, et al. Microwave tumors ablation: principles, clinical applications and review of preliminary experiences. Int J Surg. 2008;6(Suppl 1):S65–9. doi:10.1016/j.ijsu.2008.12.028.CrossRefPubMed

Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT Jr. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236(1):132–9. doi:10.1148/radiol.2361031249.CrossRefPubMed

Carrafiello G, Lagana D, Ianniello A, Dionigi G, Novario R, Recaldini C, et al. Post-radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: one centre experience and review of published works. Australas Radiol. 2007;51(6):550–4. doi:10.1111/j.1440-1673.2007.01871.x.CrossRefPubMed

Feng W, Liu W, Li C, Li Z, Li R, Liu F, et al. Percutaneous microwave coagulation therapy for lung cancer. Zhonghua zhong liu za zhi [Chinese Journal of Oncology]. 2002;24(4):388–90.PubMed

10.

Wright AS, Lee FT Jr, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol. 2003;10(3):275–83.CrossRefPubMed

11.

Skinner MG, Iizuka MN, Kolios MC, Sherar MD. A theoretical comparison of energy sources–microwave, ultrasound and laser–for interstitial thermal therapy. Phys Med Biol. 1998;43(12):3535–47.CrossRefPubMed

12.

Shock SA, Meredith K, Warner TF, Sampson LA, Wright AS, Winter TC 3rd, et al. Microwave ablation with loop antenna: in vivo porcine liver model. Radiology. 2004;231(1):143–9. doi:10.1148/radiol.2311021342.CrossRefPubMed

13.

Stauffer PR, Rossetto F, Prakash M, Neuman DG, Lee T. Phantom and animal tissues for modelling the electrical properties of human liver. Int J Hyperth. 2003;19(1):89–101.CrossRef

14.

Brace CL, Hinshaw JL, Laeseke PF, Sampson LA, Lee FT Jr. Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model. Radiology. 2009;251(3):705–11. doi:10.1148/radiol.2513081564.CrossRefPubMedPubMedCentral

15.

Durick NA, Laeseke PF, Broderick LS, Lee FT Jr, Sampson LA, Frey TM, et al. Microwave ablation with triaxial antennas tuned for lung: results in an in vivo porcine model. Radiology. 2008;247(1):80–7. doi:10.1148/radiol.2471062123.CrossRefPubMed

16.

Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9 Pt 2):S199–202.CrossRefPubMed

17.

Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, et al. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol. 2004;22(2):300–6. doi:10.1200/JCO.2004.03.097.CrossRefPubMed

18.

Pereira PL, Masala S. Cardiovascular, Interventional Radiological Society of E. Standards of practice: guidelines for thermal ablation of primary and secondary lung tumors. Cardiovasc Intervent Radiol. 2012;35(2):247–54. doi:10.1007/s00270-012-0340-1.CrossRefPubMed

19.

The National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 4.0 (2010). Bethesda: Approved after October 1, 2009.

20.

Wolf FJ, Grand DJ, Machan JT, Dipetrillo TA, Mayo-Smith WW, Dupuy DE. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology. 2008;247(3):871–9. doi:10.1148/radiol.2473070996.CrossRefPubMed

21.

Splatt AM, Steinke K. Major complications of high-energy microwave ablation for percutaneous CT-guided treatment of lung malignancies: single-centre experience after 4 years. J Med Imaging Radiat Oncol. 2015;59(5):609–16. doi:10.1111/1754-9485.12345.CrossRefPubMed

22.

de Baere T, Palussiere J, Auperin A, Hakime A, Abdel-Rehim M, Kind M, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240(2):587–96. doi:10.1148/radiol.2402050807.CrossRefPubMed

23.

Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, et al. New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010;195(3):W221–8. doi:10.2214/AJR.09.3928.CrossRefPubMedPubMedCentral

24.

Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr. 2010;34(4):479–84. doi:10.1097/RCT.0b013e3181db2670.CrossRefPubMed

25.

Egashira Y, Singh S, Bandula S, Illing R. Percutaneous high-energy microwave ablation for the treatment of pulmonary tumors: a retrospective single-center experience. J Vasc Interv Radiol. 2016;27(4):474–9. doi:10.1016/j.jvir.2016.01.001.CrossRefPubMed

26.

Carrafiello G, Mangini M, Fontana F, Ierardi AM, De Marchi G, Rotolo N, et al. Microwave ablation of lung tumours: single-centre preliminary experience. Radiol Med (Torino). 2014;119(1):75–82. doi:10.1007/s11547-013-0301-z.CrossRef

27.

Brace CL. Microwave tissue ablation: biophysics, technology, and applications. Crit Rev Biomed Eng. 2010;38(1):65–78.CrossRefPubMedPubMedCentral

28.

Ierardi AM, Mangano A, Floridi C, Dionigi G, Biondi A, Duka E, et al. A new system of microwave ablation at 2450 MHz: preliminary experience. Updates Surg. 2015;67(1):39–45. doi:10.1007/s13304-015-0288-1.CrossRefPubMed

Title: Treatment of lung tumours with high-energy microwave ablation: a single-centre experience
Authors: Anna Maria Ierardi
Andrea Coppola
Natalie Lucchina
Gianpaolo Carrafiello
Publication date: 01-01-2017
Publisher: Springer US
Published in: Medical Oncology / Issue 1/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-016-0861-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment of lung tumours with high-energy microwave ablation: a single-centre experience

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Fucoidan reduced the invasion of oral squamous cell carcinoma cells and modified their effects to macrophages

Salivary biomarkers in cancer detection

Assessment of oxidative/nitrative modifications of plasma proteins, selected ROTEM parameters and kinetics of fibrinogen polymerization in patients with multiple myeloma at diagnosis

Reply: “Patients treated with neoadjuvant chemotherapy + radical surgery + adjuvant chemotherapy in locally advanced cervical cancer: long-term outcomes, survival and prognostic factors in a single-center 10-years follow-up”

CTC clusters in cancer progression and metastasis

Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page